

Medical Marijuana (*Cannabis sativa* L.) and COVID-19: A note

Dear Editor,

Medical *Marijuana* (*Cannabis sativa* L.) is presently widely used due to legalization in many countries.^[1] An important consideration is the effect of *Marijuana* on other medical disorders. Here, the authors focus special interest on COVID-19, the new emerging coronavirus infection. A basic question is whether there is any interrelationship between the pathological pathway of coronavirus infection and the pharmacological pathway of *Marijuana*.

The authors hereby performed bioinformatics pathway analysis using primary data from mining. The reference database is PubMed. Briefly, the standard pathway interrelationship analysis is used for referencing paper.^[2] First, the common pathway was searched then creation of an interrelationship was done. Based on the present study, there is an important identified common mode between the pathological pathway of coronavirus infection and the pharmacological pathway of *Marijuana*, the Th1 and Th17 immune response was found.^[3,4] The interrelation map is shown in Figure 1. This result shows that the use of *Marijuana* can impair resistance to coronavirus infection and might be a risk for severe disease. However, an important limitation of the present informatics study is that the model is not based on COVID-19 but a highly similar coronavirus infection, Middle East respiratory distress syndrome.^[3] Further studies on *Marijuana* (*Cannabis sativa* L.) and COVID-19 *in vivo* model are required to confirm the present *in silico* study.




Figure 1: Interrelationship map between the pathological pathway of coronavirus infection and pharmacological pathway of *Marijuana*

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

Beuy Joob, Viroj Wiwanitkit*

Sanitation 1 Medical Academic Center, Bangkok Thailand, ¹Department of Community Medicine, Dr. DY Patil University, Pune, Maharashtra, India

Address for correspondence: Dr. Beuy Joob, Sanitation 1 Medical Academic Center, Bangkok Thailand. E-mail: beuyjoob@hotmail.com

References

- Hill KP. Medical Marijuana for Treatment of Chronic Pain and Other Medical and Psychiatric Problems: A Clinical Review. *JAMA*. 2015 Jun 23-30;313 (24):2474-83.
- Sriwijitalai W, Wiwanitkit V. Effect of ginseng against tuberculosis: A pathway interrelationship analysis. *Biomed Biotechnol Res J* 2019;3:120-5
- Mahallawi WH, Khabour OF, Zhang Q, Makhdoum HM, Suliman BA. MERS-CoV infection in humans is associated with a pro-inflammatory Th1 and Th17 cytokine profile. *Cytokine*. 2018 Apr;104:8-13.
- Ido JM, Jackson AR, Nagarkatti PS, Nagarkatti M. Marijuana-derived Δ -9-tetrahydrocannabinol suppresses Th1/Th17 cell-mediated delayed-type hypersensitivity through microRNA regulation. *SJ Mol Med (Berl)*. 2016 Sep; 94(9):1039-51

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

Access this article online

Quick Response Code:



Website:
www.ayujournal.org

DOI:
10.4103/ayu.ayu_276_22

How to cite this article: Joob B, Wiwanitkit V. Medical *Marijuana* (*Cannabis sativa* L.) and COVID-19: A note. *Ayu* 2022;43:32.

Submitted: 01-Nov-2022

Revised: 06-Feb-2023

Accepted: 10-Feb-2023

Published: 24-Jun-2023

© 2023 AYU (An International Quarterly Journal of Research in Ayurveda) | Official publication of Institute for Post Graduate Teaching and Research in Ayurveda, Jamnagar | Published by Wolters Kluwer - Medknow